The Disparity in Access to New Medication by Type of Health Insurance

Karl J. Krobot · William C. Miller · Jay S. Kaufman · Dale B. Christensen · John S. Preisser

59 citations0/0 files storedMedical Care

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Healthcare Policy and Management Healthcare Systems and Reforms

Abstract

BACKGROUND: Drug provision within the German statutory health insurance system has undergone several reforms, including the introduction of drug macrobudgets in 1993. OBJECTIVE: The objective of this study was to investigate the extent to which statutorily (SHI) and fully privately (PHI) health-insured patients were provided with new medication recommended by professional bodies in an equitable fashion using the example of migraine patients. RESEARCH DESIGN: We conducted a retrospective cohort study. SETTING: A total of 367 primary-care practices (MediPlus, IMS Health) in Germany in the second year of the HealthCare Structural Reform Act were studied. SUBJECTS: Subjected consisted of 7703 SHI and 470 PHI migraineurs (International Classification of Diseases, 10th edition G43) aged 18 to 65 years at their first migraine prescription visit in 1994. OUTCOME MEASURE: We compared prescription of oral or subcutaneous serotonin 5HT1B/1D receptor agonist sumatriptan with nonserotoninergic migraine therapy. RESULTS: In multiplicative risk regression with variance estimation accounting for clustering of patients within practices, PHI patients were 2.3 times (95% confidence interval [CI], 1.6-3.3) more likely to receive sumatriptan than their SHI counterparts at the mean age of the cohorts (43 years) adjusted for incident versus prevalent migraine treatment, the gender of the patient, the age, gender, and primary care specialist group of the physician, and the type and the community size class of the practice. This disparity widened by 38% (95% CI, 1-88%) every 10 years of patient age. CONCLUSION: Even though virtually everyone in Germany has health insurance and drug coverage, use of new and recommended migraine medicines was less common among those with SHI compared with their privately insured counterparts. Systematic studies of access to health care recommended by professional bodies will be critically important to ensure delivery of high-quality health care for all patients.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 59 citations exist upstream.

References

1987Health insurance and the demand for medical care: evidence from a randomized experiment.2005Technology Assessment 1993Health Insurance and Mortality 1984Termination from Medi-Cal — Does It Affect Health?1990The Association of Payer With Utilization of Cardiac Procedures in Massachusetts 1986Termination of Medi-Cal Benefits 1993A Critical Analysis of Studies of State Drug Reimbursement Policies: Research in Need of Discipline 1994Mortality in the Uninsured Compared With That in Persons With Public and Private Health Insurance

Cited by

2010Discrimination in waiting times by insurance type and financial soundness of German acute care hospitals 2012Effect of Type of Insurance and Income on Waiting Time for Outpatient Care 2020Private health insurance in Canada 2021The relationship between urban and rural health insurance and the self-rated health of migrant workers in Southwest China 2020Why private health insurance?

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.